Pharmaceuticals
Eli Lilly delivered an exceptional Q1 2026, with revenue surging 55.5% YoY to $19.8B and net income soaring 168.1% to $7.4B, driven by continued explosive demand for its GLP-1 and diabetes/obesity portfolio.
关键风险:Manufacturing Capacity Constraints
Lilly's ability to meet surging demand for its GLP-1 products depends heavily on rapid manufacturing scale-up. Cost of revenue grew 60.8% YoY, faster than revenue, suggesting ongoing production ramp costs. Any delays or failures in capacity expansion could limit revenue growth and damage market share.
同属 Pharmaceuticals 行业的其他公司